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Site-selective cAMP analogs, depending on the position of their substituents on the adenine ring, selectively 
bind to either site I or site 2 of the known cAMP binding sites of protein kinase. Treatment of Harvey 
murine sarcoma virus-transformed NIH/3T3 cells with such site-selective analogs results in growth inhibi- 
tion and phenotypic reversion, and the combination of a C-8 thio or halogen analog (site i selective) with 
an N 6 analog (site 2 selective) produces a synergistic effect. Wereport here that the growth inhibitory effect 
of the analogs correlates with the nuclear translocation of the R" cAMP receptor protein, the regulatory 
subunit of protein kinase type n. The transformed NIH/3T3 cells contained no detectable vel of R H in 
the nucleus, whereas nontransformed NIH/3T3 cells exhibited a high level of nuclear R H. Within 30 min 
after treatment of the transformed cells with the site-selective analogs, immunofluorescence against he R" 
protein markedly increased in the cell nucleus. The nuclear translocation of the R" cAMP receptor protein 
is an early event in the reverse transformation f the fibroblasts treated with site-selective cAMP analogs. 
cAMP; Protein kinase; Reverse transformation 
1. INTRODUCTION 
cAMP in mammalian cells functions by binding 
to its receptor proteins, R ~ and R II, the regulatory 
subunits of cAMP-dependent protein kinases, type 
I and type II [1,2]. The type I and type II protein 
kinases differ only in their regulatory subunits 
while the catalytic subunits are identical [3-5]. The 
physiological role of protein phosphorylation by 
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the catalytic subunit is well established [3,4], but 
the only documented function of the cAMP recep- 
tor protein is inhibition of the catalytic subunit ac- 
tivity [3]. There are, however, an increasing 
number of observations that suggest selective func- 
tional roles for the cAMP receptor proteins 
[6-10]. 
At the nuclear level, the function of the cAMP- 
dependent protein kinase catalytic subunit has 
been shown to involve chromosomal protein 
phosphorylation [11]. The role of cAMP receptor 
proteins in gene regulation has also been suggested 
[12-14]. 
We have recently reported that the site-selective 
cAMP analogs, which are selective for either one 
of the two different cAMP-binding sites on the 
cAMP receptor protein [15,16], in combination 
synergistically demonstrate growth inhibition and 
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phenotypic reversion of the Harvey murine sar- 
coma virus (Ha-MuSV)-transformed NIH/3T3 
clone 13-3B-4 cells and that the growth inhibitory 
effect of these analogs correlates with an increase 
of the R II cAMP receptor protein and a decrease of 
the R I receptor protein [17,18]. 
In the present work, we investigated, by the use 
of biochemical and immunocytochemical 
methods, the intracellular compartmentalization 
of the R n cAMP receptor protein during treatment 
of the transformed 13-3B-4 cells with the site- 
selective cAMP analogs. 
2. MATERIALS AND METHODS 
2.1. Materials 
cAMP and AP,OZ'-dibutyryl cAMP were ob- 
tained from Boehringer Mannheim Biochemicals 
(Indianapolis, IN). N6-Monobutyryl cAMP and 
8-methylthio-cAMP were obtained from Sigma 
(St. Louis, MO). All other cAMP analogs were 
synthesized atthe Nucleic Acid Research Institute 
(Costa Mesa, CA). 8-N3-[32p]cAMP (60.0 Ci/ 
mmol) was obtained from ICN (Irvine, CA). Fluo- 
rescein isothiocyanate (FITC)-conjugated goat 
anti-rabbit IgG was from Cappel Laboratories 
(Cochranville, PA). 14C-Methylated molecular 
mass marker proteins were obtained from 
Bethesda Research Laboratories (Bethesda, MD). 
2.2. Cell culture 
NIH/3T3 clone 13-3B-4 cells were grown in the 
absence or presence of additives (cAMP analogs) 
in serum-free, chemically defined medium [18] 
(Dulbecco's modified Eagle's medium-HAM's F12 
(nutrient mixture F12-HAM; 75 : 25) supplemented 
with bovine insulin (5/zg/ml), transferrin 
(5/zg/ml), histidine-HC1 (42/~g/ml), glutamine 
(292/zg/ml), penicillin (100 U/ml), streptomycin 
(100/zg/ml), and Hepes (20 mM, pH 7.3); the 
medium was changed every 48 h. The additives 
were provided every 48 h, starting at day zero of 
culture in the serum-free medium. The cells were 
grown in humidified incubators in an atmosphere 
of 10 CO2. 
2.3. Preparation of cell extracts 
All procedures were performed at 0-4°C. 
13-3B-4 cell pellets, after two washes with 
phosphate-buffered saline, were suspended in buf- 
fer Ten (0.1 M NaC1, 5 mM MgCI2, 1% Nonidet 
P-40, 0.5% Na deoxycholate, 2 KIU/ml bovine 
aprotonin, 20 mM Tris-HC1, pH 7.4) (2 × 107 
cells/ml), vortexed, passed through a 22-gauge 
needle 10 times, allowed to stand for 20 min and 
centrifuged at750 × g for 20 min, and the resulting 
supernatants were used as cell lysates. 
2.4. Preparation of cell cytosol and nuclear 
fraction 
All procedures were performed at 0-4°C. The 
cell pellets (2 × 10 7 cells), after two washes with 
phosphate-buffered saline, were suspended in 
0.5 ml buffer A (0.25 M sucrose, 2 mM MgClz, 
1 mM CaClz, 10 mM KCI, 20 mM Tris-HCl, pH 
7.5) and homogenized with a dounce homogenizer 
(60 strokes). The cytosols and nuclear fractions 
were prepared as described [19]. The purified 
nuclear pellets were suspended in 100/A buffer A 
and used as nuclear suspension. 
2.5. Photoaffinity labeling of cAMP receptor 
proteins 
The photoactivated incorporation of 8-Na- 
[3Zp]cAMP was performed as described [20]. The 
samples containing 50-75/~g of protein were sub- 
jected to 0.05% SDS-12% polyacrylamide g l elec- 
trophoresis [21]. The protein concentrations were 
determined by the method of Lowry et al. [22] with 
bovine serum albumin as standard. 
2.6. Western blotting of  R 11 cAMP receptor 
protein 
Cellular proteins present in the lysates (see 
above) were separated and transferred to 
nitrocellulose sheets [23] and first incubated with 
3% bovine serum albumin [24] and sequentially in- 
cubated with medium containing the anti-R n an- 
tibody [25,26] overnight at 4°C and 5 × 
105 cpm/ml a25I-labeled protein A for 1 h in an ice 
water bath. The nitrocellulose sheets were air dried 
and exposed to Kodak XAR film for 12 to 36 h at 
-20°C. 
2.7. Production and characterization of anti-R tI 
antibody 
The production and characterization f rabbit 
antibody against bovine heart R n has been de- 
scribed in detail [25,26]. The antibody was affinity 
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purified using a glutaraldehyde cross-linked im- 
munoabsorbent as described [27]. The 
monospecificity of antibody was confirmed as 
described in [28]. 
2.8. Immunofluorescence experiments 
Cells were seeded at 2 x 104/1.5 ml onto 
2-chamber tissue culture slides precoated with 
poly-D-lysine. After cells became attached, the 
medium was changed to the serum-free medium 
(see section 2.2) with or without additives. At 
desired culture times, the tissue culture chamber 
slides were fixed, the cells were permeabilized, and 
indirect immunofluorescence experiments were 
carried out as described [28,29] with the primary 
anti-R II antibody and FITC-conjugated goat anti- 
rabbit second antibody. The slides were viewed on 
a Zeiss epifluorescence microscope. All 
photographs were taken by using identical ex- 
posure time with a × 40 oil immersion objective 
with Kodak Tri-X film. 
The specificity of staining of R II antibody was 
assessed by the following: (i) preimmune IgG was 
used at the same concentration as that of immune 
anti-R H IgG; (ii) fixed cells were incubated with the 
FITC-conjugated goat anti-rabbit IgG without 
preincubation with the primary antibody; and (iii) 
the antibody-blocking experiments were carried 
out by preabsorbing the anti-R n antibody with R Il 
before staining. 
3. RESULTS 
3.1. Photoaffinity labeling of cAMP receptor 
proteins 
The R x and R I~ cAMP receptor proteins in the 
cytoplasmic and nuclear fractions of the control 
cells (untreated) and the cells treated with site- 
selective cAMP analogs were identified by 
photoaffinity labeling with 8-N3-[3Zp]cAMP and 
electrophoresis and quantified by densitometric 
tracings of the autoradiograms. 
As shown in f ig.lA, the untreated 13-3B-4 cells 
contained a major cAMP receptor protein with an 
Mr of 48000 in both cytosol (lane 1) and nuclear 
fraction (lane 3). A low intensity band of 
52-56 kDa receptor protein was also detected in 
the cytosol (lane 1), but the band was almost 
undetectable in the nuclear fraction (lane 3). The 
48 kDa protein appears to be the R I [1], and the 
November 1987 
52-56 kDa proteins appear to be the R n [30,31] 
cAMP receptor. These R ~ and R n bands 
represented the specific cAMP receptor proteins 
(the high affinity binding protein [1,2]), since these 
bands were absent when 1000-fold excess of 
unlabeled cAMP was present in the binding reac- 
tion (lanes 1+C,  2+C,  3+C,  and4+C) .At  3h  
after treatment of 13-3B-4 cells with N~-butyryl - 
cAMP (25/zM) + 8-methylthio-cAMP (5/zM), the 
R ~ cAMP receptor protein level in the cytosol 
decreased to 60°7o of that in the untreated cell 
cytosol; the R x receptor level in the nuclear frac- 
tion, however, did not change (fig. 1B). During this 
same period, the R H receptor protein in the nucleus 
increased 10-fold over that of untreated cells, 
whereas the cytoplasmic R n increased 3-fold 
(fig. 1B). This resulted in an increase of the RII /R I 
ratio 5- and 10-fold in the cytosol and nuclear frac- 
tion, respectively, after the analog treatment. 
At 24 h after treatment with the analog com- 
bination, R ~ further decreased while the R n re- 
mained elevated, resulting i  an increase of 6- and 
15-fold in the ratio of Rn/R ~ in the cytoplasm and 
nucleus, respectively, over those in the untreated 
control cells. Other combinations of N ~ (25/~M) 
with a C-8 thio or halogen derivative all brought 
about a similar increase in the RII/R ~ ratio to that 
shown in fig. 1. Each of these analogs singly at the 
given concentrations was without effect but was ef- 
fective at higher concentrations (N s analogs at 
100/~M; C-8 analogs at 50/~M). Thus, the same 
synergism of C-6 and C-8 analog combination was 
demonstrated on the increase of the RII /R I ratio, 
especially in the cell nucleus, as was shown on the 
growth inhibitory effect [17]. 
3.2. Western blotting of  R H cAMP receptor 
protein 
The effect of cAMP analog treatment of 13-3B-4 
cells on the amount of the R II cAMP receptor pro- 
tein was determined by Western blotting analysis 
of R I1. The antiserum used was raised in rabbit 
against bovine heart R Ix [28]. The affinity-purified 
anti-R n antibody [27] exhibited monospecificity 
for antigen R ll from human mammary cancer cells 
grown in culture [28] as well as in nude mice [32]. 
As shown in fig.2, the anti-R n antibody that 
specifically cross reacted with the R II antigen (cf. 
lanes R n and R II +CS (control serum)) but not 
with the R ~ antigen (lane R ~) detected the 
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Fig.1. Photoaffinity labeling of cAMP receptor proteins in cytosols and nuclear suspensions (NS) from untreated and 
cAMP analog-treated 13-3B-4 cells. (A) Autoradiography of photoactivated incorporation of 8-N3-[32p]cAMP followed 
by electrophoresis; (B) densitometric tracings of autoradiograms (A) at A56onm. The R ~ level in the cytosol of untreated 
cells was set equal to 1.0 .&; the scale was expanded to differentiate the lower intensity bands in NS. Lanes 1 and 3, 
untreated control cells; lanes 2 and 4, cells treated for 3 h with 25,aM N6-butyryl-cAMP + 5/zM 8-methylthio-cAMP; 
+ C, the reaction performed in the presence of 1000-fold excess unlabeled cAMP. Positions of R l and R n were identified 
by coelectrophoresis of the purified preparations (Sigma) of R 1 and R n from rabbit skeletal muscle and bovine heart, 
respectively. M, 14C-labeled molecular mass standard proteins. 
52-56 kDa R II receptor proteins from 13-3B-4 
cells. The anti-R II antibody also crossreacted with 
a lower kDa (30-39) R II species that may be pro- 
teolytic fragments of  R II [5]. Both 52-56 kDa and 
30-39 kDa R n species were absent when the anti- 
R II antibody was replaced by control serum (lane 
2+CS) ,  indicating that the proteins that 
crossreacted with the anti-bovine R II antibody all 
represent he R Ix subunits. The antibody detected 
markedly elevated levels of  the 52-56 kDa R n 
f rom the cells treated for 3 days with 50/~M 
8-methylthio-cAMP (lane 2) or 100/~M 
68K 
43K 
25.7K 
MRH1 234 
* -  52-56K R a 
5R I2  R I[ 
+ + 
CS CS 
Fig.2. Western blotting of R n cAMP receptor protein from untreated and cAMP analog-treated 13-3B-4 cells. Lanes: 
1, untreated control cells; 2-5, cells treated for 3 days with 50/~M 8-methylthio-cAMP, 5/zM 8-methylthio-cAMP +
25/zM N~-butyryl-cAMP, 5 ,aM 8-methylthio-cAMP, and 25/zM N6-butyryl-cAMP, respectively. R I and R n, purified 
preparations (Sigma) of R ~ and R n from rabbit skeletal muscle and bovine heart, respectively; 2 + CS and R n + CS, cell 
extracts of lane 2 and R n, respectively, were immunoblotted with control serum; M, ~4C-labeled kDa marker proteins. 
Each lane contained 75/~g of proteins (R I and R n were 5/zg proteins) for electrophoresis. 
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Fig.3. Immunocytochemical localization of R n cAMP receptor protein. (A,B) Untransformed NIH/3T3 cells grown in 
serum-free medium for 24 h; (C,D) Ha-MuSV-transformed NIH/3T3 clone 13-3B-4 cells grown in serum-free medium 
for 24 h; (E,F) 13-3B-4 cells treated for 30 min with 25 #M N6-butyryl-cAMP + 5 #M 8-methylthio-cAMP; (B,D,F) 
phase-contrast pictures of A, C and E, respectively, x 720. 
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N~-butyryl-cAMP (not shown) compared with that 
in untreated cells (lane 1). However, the amounts 
of lower kDa R H did not change after treatments 
with these analogs. Thus, specific increase of the 
52-56 kDa R II proteins that crossreact with the 
anti-bovine R II antibody correlated with the 
growth inhibitory effect of the analogs on 13-3B-4 
cells [17]. Furthermore, a synergistic increase in 
the band intensity of the R II was observed when the 
cells were treated with a combination of N 6 and 
C-8 analogs, which exerted synergism in the 
growth inhibition. Thus, treatment with 5/~M 
8-methylthio-cAMP added to 25/~M N6-butyryl - 
cAMP (lane 3) or 25/~M N6-carbamoylphenyl - 
cAMP (not shown) resulted in an intense R II band, 
whereas each of these analogs alone, as shown with 
5/zM 8-methylthio-cAMP (lane 4) and 25/zM 
N6-butyryl-cAMP (lane 5), brought about a low in- 
tensity band of R n. Quantification by den- 
sitometric tracings of the autoradiograms revealed 
that the analog treatments brought about a 5- to 
6-fold increase in the amount of 52-56 kDa R n 
compared with that in the untreated control cells. 
The increase in the R II detected by the im- 
munoblotting with the anti-bovine R II antibody, 
therefore, correlated with the analog's growth in- 
hibitory effect and confirmed the results previous- 
ly obtained with DEAE-cellulose chromatography 
[17]. 
3.3. Immunofluorescent localization of R II cAMP 
receptor proteins by monospecific anti-R 11 
antibody 
The ability of anti-bovine R ~ antibody to 
crossreact with the R n antigen of 13-3B-4 cells 
made possible the immunocytochemical localiza- 
tion of R H cAMP receptor proteins. As shown in 
fig.3A and B, untransformed NIH/3T3 cells 
grown for 24 h in the serum-free medium exhibited 
an extensive staining against he R H antibody. The 
antibody produced prominent staining of the 
nucleus. In addition, a granular staining of a 
perinuclear area was often visible as was shown in 
the studies [33] of immunofluorescent localization 
of the R II cAMP receptor proteins in Madine- 
Darby bovine kidney cells and rat fibroblasts. In 
contrast to untransformed NIH/3T3 cells, the 
transformed 13-3B-4 cells exhibited drastically 
reduced fluorescent labeling (fig.3C,D). Thus, 
transformation resulted in apparent loss of the 
cAMP receptor protein that crossreacts with the 
R II antibody. Strikingly, however, treatment of 
13-3B-4 cells with N6-butyryl-cAMP (25 #M) + 
8-methylthio-cAMP (5/zM) rapidly recovered the 
immunofluorescent staining in the cells. As early 
as 30 min after treatment with the analog com- 
bination, the cells exhibited an intensive fluores- 
cent labeling, especially at the nucleus (fig.3E,F); 
at 5 h after the treatment, he immunofluorescent 
staining in the cells reached its maximal intensity 
and at 24 h, the fluorescence b came less intense 
(not shown). 
Treatment of cells with either 25/~M N6-butyryl - 
cAMP or 5/~M 8-methylthio-cAMP alone for 5 h 
caused little or no immunofluorescent staining, 
whereas these analogs alone at higher concentra- 
tions (N~-butyryl-cAMP (100/~M) and 8-methyl- 
thio-cAMP (50/zM)) elicited an intense staining 
(not shown). The same synergism was 
demonstrated with other combinations of N 6 and 
C-8 analogs, which showed synergism in the 
growth inhibition and phenotypic reversion [17]. 
4. DISCUSSION 
We have shown here that the nuclear accumula- 
tion of the R n cAMP receptor protein is an early 
event in the growth inhibition and phenotypic 
reversion of the Ha-MuSV-transformed 13-3B-4 
cells treated with the site-selective cAMP analogs. 
The transformed 13-3B-4 ceils contained a 
markedly reduced level of the R H cAMP receptor 
protein compared with their nontransformed 
counterpart, NIH/3T3 cells. Within 30 min after 
treatment of 13-3B-4 cells with the site-selective 
cAMP analogs, the R I~ immunofluorescence label- 
ing sharply increased, especially in the cell nucleus. 
The combination of a site 1 (C-8 thio or halogen 
analog) and a site 2 (N 6 analog) selective analog, 
which caused a synergism in growth inhibition 
[17], demonstrated a synergistic enhancement of 
accumulation of R H in the nucleus. The nuclear 
binding of R l~ was clearly demonstrated by a more 
intense immunofluorescence staining at the 
nucleus than in the cytoplasm. The Western blot- 
ting experiments demonstrated that the anti-R u an- 
tibody specifically detected the 52-56 kDa R II of 
13-3B-4 cells. Thus, the increase in the im- 
munofluorescent staining observed in the analog- 
treated cells was due to the increase of the 
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52-56 kDa R ~x antigen in the cells. The photoaf- 
finity labeling of cAMP receptor proteins with 
8-N3-[32p]cAMP detected the R II receptor only in 
the cytoplasm but not in the nucleus of the 
transformed 13-3B-4 cells. The early increase of 
the R I~ in the nucleus of the analog-treated 13-3B-4 
cells may therefore represent translocation of the 
R u from the cytoplasm to the nucleus. 
The site-selective cAMP analogs, which are 
known to demonstrate site-selectivity [15] and 
specificity toward the R Ix receptor protein in vitro 
[16,34], induced the nuclear translocation of R H in 
intact cells in vivo. Compartmentalization in the 
cell of the cAMP-dependent protein kinase and of 
its regulatory subunit has been implicated to play 
a role in the regression of hormone-dependent 
mammary cancer [32,35] and of disorders arising 
due to viral transformation of fibroblasts [36]. 
Understanding the ultimate mechanism of cAMP 
action in the modulation of gene activity would 
provide insights into the regulatory mechanism for 
cell proliferation and transformation. 
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